Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20033536 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17256295 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL13483316 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL14864297 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL18723048 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL23723836 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL16504207 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17154136 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL14802349 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL15293443 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110236930-A1 | CHEMOSELECTIVE LIGATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-29 | — | — | US | disclosed |
| US-7939626-B2 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-10 | — | — | US | disclosed |
| US-7923582-B2 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-04-12 | — | — | US | disclosed |
| US-7838665-B2 | Chemoselective ligation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-23 | — | — | US | disclosed |
| US-7667012-B2 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product; N-azidogalactosamine | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-04 | — | — | US | disclosed |
| US-20070037964-A1 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236930-A1 | CHEMOSELECTIVE LIGATION | PTMS, QPCT, DNPEP | LGALS8 3792/4885L3MBTL1 616/4885MAPT 4467/4885 |
| US-20070037964-A1 | Condensation of a specifically engineered phosphine containing a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine by-product and producing an amide bond in final product | PTMS, PHOSPHO1, QPCT | LGALS8 3605/4885L3MBTL1 1151/4885MAPT 3867/4885 |
| US-20080214801-A1 | CHEMOSELECTIVE LIGATION | PTMS, QPCT, DNPEP | LGALS8 3792/4885L3MBTL1 616/4885MAPT 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.